Robert F. Kennedy Jr. remains HHS Secretary after a narrow 52-48 Senate confirmation in February 2025, with traders implying a 71% chance he stays through December 31, 2026, reflecting White House backing despite persistent criticism. Recent staff turnover, including his chief spokesperson's resignation this week over FDA flavored e-cigarette policy disputes, has not triggered dismissal signals, echoing earlier 2025 calls for resignation from medical groups and HHS employees that went unheeded. Ongoing leadership shakeups at HHS in February 2026 and defense of the fiscal year 2026 budget underscore his entrenched role in executing the administration's health priorities, absent major scandals or midterm election pressures to force an exit.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트$18,824 거래량
$18,824 거래량
$18,824 거래량
$18,824 거래량
An announcement of Robert F. Kennedy Jr. (RFK Jr.)'s resignation/removal before this market's end date will immediately resolve this market to "Yes", regardless of when the announced resignation/removal goes into effect.
The resolution source for this market will be official information from Robert F. Kennedy Jr. (RFK Jr.) and the U.S. government; however, a consensus of credible reporting may also be used.
마켓 개설일: Mar 19, 2026, 2:02 PM ET
Resolver
0x65070BE91...An announcement of Robert F. Kennedy Jr. (RFK Jr.)'s resignation/removal before this market's end date will immediately resolve this market to "Yes", regardless of when the announced resignation/removal goes into effect.
The resolution source for this market will be official information from Robert F. Kennedy Jr. (RFK Jr.) and the U.S. government; however, a consensus of credible reporting may also be used.
Resolver
0x65070BE91...Robert F. Kennedy Jr. remains HHS Secretary after a narrow 52-48 Senate confirmation in February 2025, with traders implying a 71% chance he stays through December 31, 2026, reflecting White House backing despite persistent criticism. Recent staff turnover, including his chief spokesperson's resignation this week over FDA flavored e-cigarette policy disputes, has not triggered dismissal signals, echoing earlier 2025 calls for resignation from medical groups and HHS employees that went unheeded. Ongoing leadership shakeups at HHS in February 2026 and defense of the fiscal year 2026 budget underscore his entrenched role in executing the administration's health priorities, absent major scandals or midterm election pressures to force an exit.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트
외부 링크에 주의하세요.
외부 링크에 주의하세요.
자주 묻는 질문